摘要
目的探讨雷贝拉唑预防急性脑血管病并发急性胃粘膜病变的作用。方法对86例急性脑血管病患者随机分成治疗组43例和对照组43例,治疗组在常规治疗的基础上根据病情轻重给予雷贝拉唑20mg,口服每日1次×15d。结果对照组12例并发急性胃粘膜病变,发病率27.9%,治疗组2例发生急性胃粘膜病变,发病率6.97%(P<0.01),对照组死亡9例,病死率20.9%,治疗组死亡2例,病死率4.65%(P<0.025)。结论雷贝拉唑预防急性脑血管病并发急性胃粘膜病变安全有效,能明显减少发病率和病死率,临床可常规应用。
Objectives to investigate the effect of rabeprazole in preventing acute gastric mucosallesion in patients with acute cerebrovascular disease （AVCD）. Methods 86 patients with AVCD are divided into two groups at random One is treatment group and the other is control group. Besides the conventional therapy, the first group is treated with rabeprazole in the dosage of 40 mg （iv, bid） for 3 or 5 days, then 20 mg （po,bid） for ten days. Results There are two paatents having acute gastric mucosallesion in treatment group, the morbility is 2.3%. 12 patients having acute gastric mucosallesion in control group, the morbility is 27.9% （P 〈 0.01）. Two patients died in the treatment group and the mortality is 4.65%. 9 patients died in control group, the mertality is 20.9% （P 〈 0.025）. Conclusion Rabeprazole can effective and safely prevent acute gastric mucosallesion in patients with acute cerebrovascular. It can be used as a conventional therapeutic drug in clinic because it can decrease the morbolity and mortality of the patients.
出处
《医学综述》
2006年第5期319-320,共2页
Medical Recapitulate
关键词
脑血管病
急性胃黏膜病变
雷贝拉唑
制酸
Cerebrovascular disease
Acute gastric mucosallesion
Rabeprazole
Restrain acid
